Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1134-1145

  Krysiak, Robert ^a   Łabuzek, Krzysztof ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipokines; Adipose tissue; Cell cultures; Hypolipidemic agents; Pleiotropic effects

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ATORVASTATIN; FENOFIBRIC ACID; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DYSLIPIDEMIA; FEMALE; HORMONE ACTION; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; MALE; PLEIOTROPY; SUBCUTANEOUS FAT; SUBCUTANEOUS TISSUE; VISCERA;

EID: 76049108649     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70176-8     Document Type: Article

References (41)

1. Alegret M, Silvestre JS: Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol, 2006, 28, 627-656.
2. Anderlová K, Dolezalová R, Housová J, Bosanská L, Haluzíková D, Kremen J, Skrha J, Haluzik M: Influence of PPAR-α agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res, 2007, 56, 579-586.
3. Backes JM, Gibson CA, Howard PA: Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag, 2005, 1, 317-331.
4. Bianchi C, Penno G, Romero F, Del Prato S, Miccoli R: Treating the metabolic syndrome. Expert Rev Cardiovasc Ther, 2007, 5, 491-506.
5. Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A et al.: Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol, 2008, 586, 259-265.
6. Bruun JM, Pedersen SB, Kristensen K, Richelsen B: Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol, 2002, 190, 91-99.
7. Calabro P, Yeh ET: Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem, 2008, 42, 63-91.
8. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, Shinomiya K et al.: Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J, 2007, 71, 144-152.
9. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH et al.: Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats. Biochem Biophys Res Commun, 2005, 336, 747-753.
10. Chu CH, Lee JK, Lam HC, Lu CC, Sun CC, Wang MC, Chuang MJ, Wei MC: Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest, 2008, 31, 42-47.
11. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT: Effects of atorvastatin and atorvastatin withdrawal on soluble CD40Land adipocytokines in patients with hypercholesterolaemia. Acta Cardiol, 2006, 61, 263-269.
12. Chudek J, Wiȩcek A: Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep, 2006, 58, Suppl, 81-88.
13. Damci T, Tatliagac S, Osar Z, Ilkova H: Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med, 2003, 14, 357-360.
14. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 2004, 145, 2273-2282.
15. Gannagé-Yared MH, Azar RR, Amm-Azar M, Khalifé S, Germanos-Haddad M, Neemtallah R, Halaby G: Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism, 2005, 54, 947-951.
16. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS: Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol, 2008, 68, 536-541.
17. Govindarajan G, Alpert MA, Tejwani L: Endocrine and metabolic effects of fat: cardiovascular implications. Am J Med, 2008, 121, 366-370.
18. Gualillo O, González-Juanatey JR, Lago F: The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med, 2007, 17, 275-283.
19. Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z et al.: Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-α agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology, 2006, 147, 4517-4524.
20. He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B: Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm Metab Res, 2003, 35, 18-23.
21. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D et al.: Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol, 2007, 27, 635-641.
22. Hung YJ, Pei D, Wu DA, Kuo SW, Fuh MM, Jeng C: Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol. J Formos Med Assoc, 1999, 98, 104-110.
23. Jasińska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep, 2007, 59, 483-499.
24. Jeong S, Han M, Lee H, Kim M, Kim J, Nicol CJ, Kim BH et al.: Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism, 2004, 53, 1284-1289.
25. Keating GM, Ormrod D: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 2002, 62, 1909-1944.
26. Kirkland JL, Tchkonia T, Giordadze N, Pirtskhalava T: Adipose tissue as an endocrine organ: regional differences in adipocyte endocrine function. In: Progress in Obesity Research. Eds. Medeiros-Neto G, Halpern A, Bouchard C, John Libbey Eurotext Ltd, Paris, 2003, 87-95.
27. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK: Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol, 2005, 45, 1649-1653.
28. Laumen H, Skurk T, Hauner H: The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis, 2008, 196, 565-573.
29. 4 ) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem, 2004, 279, 34411-34420.
30. Murata M, Kaji H, Takahashi Y, Iida K, Mizuno I, Okimura Y, Abe H, Chihara K.: Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro. Biochem Biophys Res Commun, 2000, 270, 343-348.
31. Ogawa S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, Sato T: Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism, 2000, 49, 331-334.
32. Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K: Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J, 2007, 54, 431-435.
33. Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, Parhofer KG: Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol, 2007, 44, 65-68.
34. Saito S, Fujiwara T, Matsunaga T, Minagawa K, Fukui K, Fukuda I, Osanai T, Okumra K.: Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress. Atherosclerosis, 2008, 199, 378-383.
35. Scott CL: Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol, 2003, 92, Suppl, 35-42.
36. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. Nature, 1998, 393, 790-793.
37. Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, Kihara S et al.: Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis, 2008, 196, 114-121.
38. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 2006, 86, 515-581.
39. Undas A, Celińska-Löwenhoff M, Domagała TB, Iwaniec T, Dropiński J, Löwenhoff T, Szczeklik A: Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost, 2005, 94, 193-199.
40. Yin WH, Jen HL, Chen JW, Lin SJ, Young MS: Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab, 2006, 32, 229-235.
41. Yin X, Tu L, Yang H: Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes. J Huazhong Univ Sci Technolog Med Sci, 2007, 27, 248-251.